Transparency Document

NCCN Guidelines for Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma V.2.2025

Request Number Guideline Page Specific change request Panel Decision Comment Institution Vote
4790 - Internal Request WM/LPL-B (2 of 4) and WM/LPL-B (3 of 4) Consider adding a footnote to rituximab regimens: Obinutuzumab may be considered in patients who are unable to tolerate rituximab (Wróbel T, et al. Hemasphere 2023;7:e4339598. doi: 10.1097/01.HS9.0000971308.43395.98).  Change made The panel agreed to add the footnote for rituximab regimens. Yes: 18
No: 2
Abstain:1
Absent:13